Literature DB >> 4028024

Surface antigens of melanomas and melanocytes defined by mouse monoclonal antibodies: specificity analysis and comparison of antigen expression in cultured cells and tissues.

F X Real, A N Houghton, A P Albino, C Cordon-Cardo, M R Melamed, H F Oettgen, L J Old.   

Abstract

Mouse monoclonal antibodies (mAb) detecting 13 distinct systems of surface antigens on cultured melanocytes and melanomas were tested for reactivity with panels of (a) normal and malignant cultured cells; (b) normal adult and fetal tissues; and (c) specimens of metastatic melanoma and other tumor types. The objectives of this study were to compare antigen expression in cultured versus noncultured cells, to develop a panel of mAbs that identify subsets of melanomas, and to provide requisite information about antibody specificity in preparation for the use of antibodies in the diagnosis, imaging, and therapy of melanoma. Five of the melanoma surface antigens have been well characterized biochemically [GD3, chondroitin sulfate proteoglycan, HLA Class II antigens, glycoprotein of molecular weight 130,000 (gp130), and glycoprotein Mr 95,000/protein Mr 97,000 (gp95/p97)]. Three antigens have been related to melanocyte differentiation (HLA Class II, M111/M231, and M144), and six provide additional markers for subsets of cultured melanomas. mAb R24 reacts with the disialoganglioside GD3, a predominant ganglioside on cultured melanoma cells and other cells of neuroectodermal origin. A high proportion of melanoma, astrocytoma, and sarcoma tissue specimens were GD3+. In normal tissues, reactivity of mAb R24 was restricted to melanocytes, neuronal and glial cells in the central nervous system, parotid gland, adrenal medullary cells, and rare cells in the connective tissue. mAb B5 detects a chondroitin sulfate proteoglycan that is expressed by most melanoma and astrocytoma cell lines and by cultured melanocytes. Most of the melanoma and astrocytoma specimens were B5+, whereas other tumor types tested were B5-. mAb 13-17, which detects a monomorphic determinant of HLA Class II antigens, reacted with melanomas, and with a variety of other cancers, but not with normal skin melanocytes. There is considerable variability in the expression of GD3 and HLA Class II antigens in individual melanoma specimens; cotyping for these two antigens showed no evidence for coordinate expression. mAb L101 detects gp130 and mAb L235 detects gp95, antigens that are strongly expressed on a broad range of cultured cell types. In contrast to their wide distribution on cultured cells, gp130 expression in tissues was generally restricted to a subset of melanomas and some normal cells, and gp95 was detected on only a small number of melanomas. mAb M111/mAb M231 and mAb M144 define intermediate and late stage differentiation markers of cultured melanocytes and melanomas.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4028024

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  32 in total

1.  The multi-PDZ domain protein MUPP1 is a cytoplasmic ligand for the membrane-spanning proteoglycan NG2.

Authors:  D S Barritt; M T Pearn; A H Zisch; S S Lee; R T Javier; E B Pasquale; W B Stallcup
Journal:  J Cell Biochem       Date:  2000-08-02       Impact factor: 4.429

2.  Expression of gelatinase B and the extracellular matrix metalloproteinase inducer EMMPRIN in benign and malignant pigment cell lesions of the skin.

Authors:  J J van den Oord; L Paemen; G Opdenakker; C de Wolf-Peeters
Journal:  Am J Pathol       Date:  1997-09       Impact factor: 4.307

3.  Cell adhesion to anosmin via α5β1, α4β1, and α9β1 integrins.

Authors:  Yukinori Endo; Hiroko Ishiwata-Endo; Kenneth M Yamada
Journal:  Cell Adh Migr       Date:  2018-02-20       Impact factor: 3.405

4.  Cell surface molecules of human melanoma. Immunohistochemical analysis of the gp57, GD3, and mel-CSPG antigenic systems.

Authors:  P Garin-Chesa; H R Beresford; A Carrato-Mena; H F Oettgen; L J Old; M R Melamed; W J Rettig
Journal:  Am J Pathol       Date:  1989-02       Impact factor: 4.307

Review 5.  The potential complementary role of targeted alpha therapy in the management of metastatic melanoma.

Authors:  Michael P Brown; Eva Bezak; Barry J Allen
Journal:  Melanoma Manag       Date:  2015-11-24

Review 6.  HLA class II antigen-processing pathway in tumors: Molecular defects and clinical relevance.

Authors:  Barbara Seliger; Matthias Kloor; Soldano Ferrone
Journal:  Oncoimmunology       Date:  2017-02-06       Impact factor: 8.110

7.  Induction of IgG antibodies against GD3 ganglioside in rabbits by an anti-idiotypic monoclonal antibody.

Authors:  P B Chapman; A N Houghton
Journal:  J Clin Invest       Date:  1991-07       Impact factor: 14.808

8.  DNA content and MHC class II antigen expression in malignant melanoma: clinical course.

Authors:  J Zaloudik; M Moore; A K Ghosh; Z Mechl; A Rejthar
Journal:  J Clin Pathol       Date:  1988-10       Impact factor: 3.411

9.  Antibody response after immunization with the gangliosides GM1, GM2, GM3, GD2 and GD3 in the mouse.

Authors:  P O Livingston; G Ritter; M J Calves
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

10.  Antitumor effects of a novel monoclonal antibody with high binding affinity to ganglioside GD3.

Authors:  S Ohta; A Honda; Y Tokutake; H Yoshida; N Hanai
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.